Comparison of survival with somatostatin analog and chemotherapy and prognostic factors for treatment in 165 advanced neuroendocrine tumor patients with Ki-67 20% or less

Simple item page
dc.contributor.authorÖzaslan E.
dc.contributor.authorKaraca H.
dc.contributor.authorKoca S.
dc.contributor.authorSevinc A.
dc.contributor.authorHacioglu B.
dc.contributor.authorÖzkan M.
dc.contributor.authorÖzcelik M.
dc.contributor.authorDuran A.O.
dc.contributor.authorHacibekiroglu I.
dc.contributor.authorYildiz Y.
dc.contributor.authorTanriverdi O.
dc.contributor.authorMenekse S.
dc.contributor.authorAksoy A.
dc.contributor.authorBozkurt O.
dc.contributor.authorUrvay S.
dc.contributor.authorUysal M.
dc.contributor.authorDemir H.
dc.contributor.authorCiltas A.
dc.contributor.authorDane F.
dc.date.accessioned2024-07-22T08:11:33Z
dc.date.available2024-07-22T08:11:33Z
dc.date.issued2016
dc.description.abstractThe objectives of this study were to compare progression-free survival (PFS) with somatostatin analog (SSA) versus chemotherapy (CTx) in first-line therapy and to determine the patient group in which these treatments were more effective in neuroendocrine tumors (NETs) with a Ki-67 index of 20% or less. Patients who received SSA or CTx and had unresectable locally advanced and metastatic NETs with a Ki-67 index of 20% or less were retrospectively selected from 13 centers in the Turkish database between 2000 and 2015. One hundred and sixty-five patients were enrolled. The median age was 56 years and the male-to-female ratio was 1.09. Seventy-four (45%) patients were of grade 1 NET and 91 (55%) were of grade 2. SSA was given to 104 patients, whereas 61 were treated with CTx. The objective response rate after SSA was 15.4%; another 73.1% had stable disease. The objective response rate after CTx was 36.1%, and 40.9% had stable disease (P=0.008). The median PFS in SSA patients was 21 months (95% confidence interval: 12.4-29.6), and 8 months for CTx (95% confidence interval: 5.5-10.6) (P<0.001). There was no significant difference between PFS of receiving SSA and CTx in pancreatic neuroendocrine tumor (PNET) patients; however, the PFS of receiving SSA was longer in non-PNET patients (P<0.001). SSA was better treatment in advanced NET patients with a Ki-67 index of less than 5%, having a primary resected and a performance status of 0 (P<0.05). SSA may be preferred over CTx in advanced NET patients with low-to-intermediate grade. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
dc.identifier.DOI-ID10.1097/CAD.0000000000000445
dc.identifier.issn09594973
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/15690
dc.language.isoEnglish
dc.publisherLippincott Williams and Wilkins
dc.subjectAdult
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectDisease-Free Survival
dc.subjectFemale
dc.subjectHumans
dc.subjectKi-67 Antigen
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectNeuroendocrine Tumors
dc.subjectOctreotide
dc.subjectPeptides, Cyclic
dc.subjectRetrospective Studies
dc.subjectSomatostatin
dc.subjectalkaline phosphatase
dc.subjectangiopeptin
dc.subjectcapecitabine
dc.subjectchromogranin A
dc.subjectcisplatin
dc.subjectetoposide
dc.subjectgallium 68
dc.subjectKi 67 antigen
dc.subjectoctreotide
dc.subjectsomatostatin derivative
dc.subjecttemozolomide
dc.subjectangiopeptin
dc.subjectantineoplastic agent
dc.subjectcyclopeptide
dc.subjectKi 67 antigen
dc.subjectsomatostatin
dc.subjectadult
dc.subjectadvanced cancer
dc.subjectalkaline phosphatase blood level
dc.subjectArticle
dc.subjectcancer chemotherapy
dc.subjectcancer patient
dc.subjectcancer survival
dc.subjectcarcinoid syndrome
dc.subjectdisease duration
dc.subjectfemale
dc.subjectfollow up
dc.subjecthistopathology
dc.subjecthuman
dc.subjecthuman tissue
dc.subjectleukocyte count
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmiddle aged
dc.subjectneuroendocrine tumor
dc.subjectoverall survival
dc.subjectpancreatic neuroendocrine tumor
dc.subjectpositron emission tomography
dc.subjectpriority journal
dc.subjectprogression free survival
dc.subjectretrospective study
dc.subjecttreatment response
dc.subjectaged
dc.subjectanalogs and derivatives
dc.subjectclinical trial
dc.subjectcomparative study
dc.subjectdisease free survival
dc.subjectmetabolism
dc.subjectmulticenter study
dc.subjectNeuroendocrine Tumors
dc.subjectvery elderly
dc.titleComparison of survival with somatostatin analog and chemotherapy and prognostic factors for treatment in 165 advanced neuroendocrine tumor patients with Ki-67 20% or less
dc.typeArticle

Files

Collections

Scopus Koleksiyonu